Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
14.76
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
16
17
Next >
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
September 19, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
September 16, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
July 21, 2022
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
September 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
7 Stocks Under $15 to Buy and Hold Forever
September 01, 2022
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul.
Via
InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 30, 2022
Via
Benzinga
Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate
August 30, 2022
The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of...
Via
Benzinga
With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report
August 30, 2022
Via
Benzinga
Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26
August 26, 2022
CNBC The Aviation Sector Is Slammed By Sky-High Rents
Via
Benzinga
After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact
August 26, 2022
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 22, 2022
Via
Benzinga
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried
August 22, 2022
Shares hit their lowest point since November on the FDA's decision in HAE.
Via
Investor's Business Daily
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
August 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Peering Into Takeda Pharmaceutical's Recent Short Interest
August 08, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold...
Via
Benzinga
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
July 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
July 27, 2022
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome...
Via
Benzinga
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
July 26, 2022
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could...
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents
July 26, 2022
Via
Benzinga
Peering Into Takeda Pharmaceutical's Recent Short Interest
July 21, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which...
Via
Benzinga
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
July 21, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
July 19, 2022
Upgrades
Via
Benzinga
Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful
July 18, 2022
Via
Benzinga
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
July 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Looking Into Takeda Pharmaceutical's Recent Short Interest
July 05, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which...
Via
Benzinga
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
July 01, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
Via
Benzinga
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
June 30, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
June 27, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
June 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
As Health Problems Mount Patients Welcome New Treatments
June 14, 2022
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...
Via
FinancialNewsMedia
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.